SEC CIK 1142630
CULLEN JAMES
Reported ownership across 4 companies, sourced from SEC Form 4 filings and updated daily.
Current Positions
| Company | Shares Owned | As Of |
|---|---|---|
| Aview stock → | 76,472.56 | 2017-05-24 |
| KEYSview stock → | 21,821 | 2026-06-02 |
| PRUview stock → | 4,006 | 2017-05-09 |
| JNJview stock → | 1,489 | 2014-09-10 |
Position History — A
Reported shares owned immediately after each Form 4 transaction, over time.
Recent Filings — A
| Date | Activity | Shares | Price | Owned After |
|---|---|---|---|---|
| 2017-05-24 | Option exercise (derivative) | 15,482 | $0.00 | 0 |
| 2017-05-24 | Open-market sale | 15,482 | $59.04 | 76,472.56 |
| 2017-05-24 | Option exercise | 15,482 | $13.89 | 91,954.56 |
| 2017-03-16 | Grant / award | 3,866 | $53.05 | 76,299.08 |
| 2016-08-22 | Open-market sale | 13,574 | $47.52 | 72,042.37 |
| 2016-05-27 | Option exercise (derivative) | 8,072 | $0.00 | 0 |
| 2016-05-27 | Open-market sale | 16,697 | $45.78 | 84,541.31 |
| 2016-05-27 | Option exercise | 8,072 | $24.22 | 92,613.31 |
| 2016-05-27 | Option exercise | 8,625 | $26.16 | 101,238.31 |
| 2016-05-23 | Open-market sale | 16,922 | $44.63 | 84,541.31 |
| 2016-05-23 | Open-market sale | 16,333.2 | $44.63 | 85,440.31 |
| 2016-05-23 | Open-market sale | 589 | $44.63 | 1,499.23 |
| 2016-03-17 | Grant / award | 4,704 | $39.29 | 101,264.37 |
| 2015-10-06 | Option exercise (derivative) | 8,870 | $0.00 | 0 |
| 2015-10-06 | Option exercise | 8,870 | $24.15 | 96,145.4 |
| 2015-03-19 | Grant / award | 4,311 | $42.21 | 86,932.16 |
| 2014-03-20 | Grant / award | 3,158 | $56.69 | 63,019.91 |
| 2013-11-19 | Option exercise (derivative) | 3,464 | $0.00 | 0 |
| 2013-11-19 | Open-market sale | 8,496 | $54.03 | 59,750.97 |
| 2013-11-19 | Option exercise | 5,032 | $21.72 | 64,782.97 |
| 2013-11-19 | Option exercise | 3,464 | $32.40 | 68,246.97 |
| 2013-05-17 | Open-market sale | 8,329 | $45.31 | 59,499.15 |
| 2013-03-21 | Grant / award | 4,250 | $41.65 | 67,685.83 |
| 2012-03-22 | Grant / award | 4,079 | $43.71 | 62,918.1 |
| 2011-12-12 | Option exercise (derivative) | 4,789 | $0.00 | 0 |
| 2011-12-12 | Open-market sale | 4,789 | $33.48 | 58,839.1 |
| 2011-12-12 | Option exercise | 4,789 | $30.81 | 63,628.1 |
| 2011-06-21 | Option exercise (derivative) | 13,638 | $0.00 | 0 |
| 2011-06-21 | Option exercise | 13,638 | $12.22 | 72,477.1 |
| 2011-06-21 | Open-market sale | 13,638 | $49.91 | 58,839.1 |
| 2011-03-02 | Grant / award | 3,619 | $41.46 | 58,839.1 |
| 2010-12-22 | Option exercise (derivative) | 4,132 | $0.00 | 0 |
| 2010-12-22 | Open-market sale | 4,132 | $40.95 | 55,220.1 |
| 2010-12-22 | Option exercise | 4,132 | $34.95 | 59,352.1 |
| 2010-03-03 | Grant / award | 4,935 | $32.44 | 55,220.1 |
| 2009-03-12 | Grant / award | 5,081.3 | $13.81 | 50,285.1 |
| 2008-12-01 | Grant / award | 3,910.77 | $17.26 | 45,203.8 |
| 2008-11-18 | Grant / award (derivative) | 11,312 | $0.00 | 11,312 |
| 2008-09-02 | Grant / award | 1,957.09 | $34.49 | 41,293.03 |
| 2008-06-02 | Grant / award | 1,829.27 | $36.90 | 39,335.94 |
| 2008-03-03 | Grant / award | 2,335.72 | $30.74 | 37,506.67 |
| 2008-03-03 | Grant / award | 2,195.84 | $30.74 | 35,170.95 |
| 2007-12-03 | Grant / award | 1,721.85 | $37.75 | 32,975.11 |
| 2007-11-19 | Grant / award (derivative) | 6,302 | $0.00 | 6,302 |
| 2007-09-04 | Grant / award | 1,782.78 | $36.46 | 31,253.26 |
| 2007-06-01 | Grant / award | 1,698.01 | $38.28 | 29,470.48 |
| 2007-03-01 | Grant / award | 1,995.7 | $31.44 | 27,772.47 |
| 2007-03-01 | Grant / award | 2,080.67 | $31.24 | 25,776.77 |
| 2006-12-04 | Grant / award | 2,007.41 | $32.38 | 23,696.1 |
| 2006-11-15 | Grant / award (derivative) | 5,898 | $0.00 | 5,898 |
| 2006-11-01 | Open-market buy | 1,240.7 | $33.90 | 21,688.69 |
| 2006-09-05 | Grant / award | 2,079.34 | $31.26 | 20,447.99 |
| 2006-06-02 | Grant / award | 1,843.97 | $35.25 | 18,368.65 |
| 2006-03-02 | Grant / award | 1,785.71 | $36.40 | 14,672.3 |
| 2006-03-02 | Grant / award | 1,852.38 | $35.09 | 16,524.68 |
Source: SEC EDGAR Form 4 filings. For informational purposes only — not investment advice.